Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SAR408701 |
Synonyms | |
Therapy Description |
SAR408701 is an anti-CEACAM5 antibody in conjugation with DM4, which may lead to specific toxicity towards CEACAM5-expressing tumor cells (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR408701 | SAR-408701|Tusamitamab ravtansine | SAR408701 is an anti-CEACAM5 antibody in conjugation with DM4, which may lead to specific toxicity towards CEACAM5-expressing tumor cells (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Recruiting | USA | FRA | ESP | BEL | 0 |
NCT04154956 | Phase III | SAR408701 Docetaxel | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT05245071 | Phase II | SAR408701 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) | Recruiting | ITA | FRA | ESP | BEL | 2 |